Skip to the story
Morning ColumnFree letter

Current News · Sourced report

FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma

The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carci

News Desk · Nov 5, 2026 · U.S. Food and Drug Administration

Open the source

This item is a public release from the U.S. Food and Drug Administration. The source date is Nov 5, 2026. The next paragraph is the agency's own short text. Morning Column did not rewrite it.

The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherap

The full release is on the source page. This page is not personal medical advice.

This page is general information from the sources below. It is not personal medical advice, a diagnosis, or a treatment plan. Talk with a qualified clinician about your own health. Read the disclaimer.

References

  1. U.S. Food and Drug Administration. FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma. Nov 5, 2026.

See a factual error? Write to contact@morningcolumn.com. The corrections log is public.